drugset / Trial / NCT07284043
A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
NaSingle-groupOpen-labelTreatment
Summary
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.
Timeline
- Start
- 2025-11-30
- Primary completion
- 2026-11
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT1013 | Peptide | — | — |